Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3653-3659

  Berglundi, Ake ^a   Edler, David ^b   Molin, Daniel ^a   Nordlinder, Hans ^a   Graf, Wilhelm ^a   Glimelius, Bengt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Colorectal carcinoma; p53; Palliative chemotherapy; Predictive value; TS

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; PROTEIN P53; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036875104     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ragnhammar P, Hafstrom L, Nygren P and Glimelius B: A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40(2-3): 282-308, 2001.
2. Assersohn L, Norman A, Cunningham D, Benepal T, Ross J and Oates J: Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 79(11-12): 1800-5, 1999.
3. Graf W, Bergstrom R, Pahlman L and Glimelius B: Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 4: 453-7, 1994.
4. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17(6): 1760-70, 1999.
5. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P and Catalano G: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5(8): 1996-9, 1999.
6. Davies MM, Hohnston PG, Kaur S and Allen-Mersh TG: colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5(2): 102-8, 1999.
7. Iqbal S and Lenz HJ: Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3(2): 102-8, 2001.
8. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55(7): 1407-12, 1995.
9. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly lucovorin. J Clin Oncol 15(10): 3223-9, 1997.
10. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: and analysis of response and survival. Clin Cancer Res 4(5): 1243-50, 1998.
11. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6(4): 1322-7, 2000.
12. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG: Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82(3): 560-7, 2000.
13. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75(6): 903-9, 1997.
14. McLeod HL and Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 79(2): 191-203, 1999.
15. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B and Lindmark G: Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17(2): 593-9, 1999.
16. Bergh J, Norberg T, Sjogren S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1(10): 1029-34, 1995.
17. Chang F, Syrjanen J and Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13(4): 1009-22, 1995.
18. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF and Cohen AM: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14(10): 2696-701, 1996.
19. Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staccioli MP, Baldelli AM, Brenna A, Valenti A, Muretto P and Catalano G: Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination;
20. Glimelius B: Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol 4(3): 235-40, 1993.
21. Glimelius B, Graf W, Hoffman K, Pahlman L, Sjoden PO and Wennberg A: General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. Acta Oncol 31(6): 645-51, 1992.
22. Glimelius B, Jakobsen A, Graf W, Berglund A, Gadeberg C, Hansen P, Kjaer M, Brunsgaard N, Sandberg E, Lindberg B, Sellstrom H, Lorentz T, Pahlman L and Gustavsson B: Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 34(5): 674-8, 1998.
23. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12(12): 2640-7, 1994.
24. Aschele C, Debernardis D, Tunesi G, Maley F and Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6(12): 4797-84, 2000.
25. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6(4): 1378-84, 2000.
26. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M and Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 82(1): 70-7, 1998.
27. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7(3): 193-8, 2000.
28. Kuukasjarvi T, Kononen J, Helin H, Holli K and Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14(9): 2584-9, 1996.
29. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Phlman L, Lindmark G and Blomgren H: Immunohistochemically detected thymidylate synthase in colorectal cancer: and independent prognostic factor of survival. Clin Cancer Res 6(2): 488-92, 2000.
30. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voom DA, Smid K, Hoekman K, Hoitsma HF and Peters GJ: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer [In Process Citation]. Clin Cancer Res 6(3): 1063-72, 2000.
31. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV and Leichman LP: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4(5): 1227-34, 1998.
32. Tachikawa D, Arima S and Futami K: Immunohistochemical expression of thymidylate synthase as a prognostic factor and as a chemotherapeutic efficacy index in patients with colorectal carcinoma. Anticancer Res 20(6A): 4103-7, 2000.
33. Kressner U, Lindmark G, Gerdin B, Pahlman L and Glimelius B: Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16(2): 951-7, 1996.
34. Baas IO, Mulder JW, Offerhaus GJ, Bogelstein B and Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172(1): 5-12, 1994.
35. Sanguedolce R, Vultaggio G, Sanguedolce F et al: The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18: 1515-1520, 1998.
36. Sjogren S, Inganas M, Norberg T et al: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182, 1996.
37. Lenz HJ, Hayashi K, Salonga D et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.